Oral Contraceptives Lower Ovarian Cancer Risk in BRCA Carriers

Findings seen in BRCA1 and BRCA2 mutation carriers; reduction greater with longer duration of use in BRCA1 carriers
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Internal Medicine, Oncology, Pharmacy, Journal, Source Type: news

Related Links:

This article reviews the abnormal expression of miR-802 in a variety of tumors, expounds the mechanism by which miR-802 affects tumor progression by regulating different target genes, and elaborates the network of miR-802-related ceRNAs. We also summarized the limitations of miR-802 research and looked forward to the potential application of miR-802 in the diagnosis and prognosis of tumors.PMID:34558723 | DOI:10.1002/jcla.23989
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conclusions  Once weekly selinexor in combination with topotecan was viable and showed some preliminary tumor efficacy. The recommend phase 2 dose of selinexor was 60  mg once weekly in combination with IV topotecan.Trial registration: NCT02419495. Registered 14 April 2015,https://clinicaltrials.gov/ct2/show/NCT02419495
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate canc...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
AbstractEstrogens have pleiotropic effects on many reproductive and non-reproductive tissues and organs including the mammary gland, uterus, ovaries, vagina, and endothelium. Estrogen receptor  α functions as the principal mediator of estrogenic action in most of these tissues. Estetrol (E4) is a native fetal estrogen with selective tissue actions that is currently approved for use as the estrogen component in a combined oral contraceptive and is being developed as a menopause hormone t herapy (MHT, also known as hormone replacement therapy). However, exogenous hormonal treatments, in particular MHTs, have been ...
Source: Journal of Mammary Gland Biology and Neoplasia - Category: Cancer & Oncology Source Type: research
Pharmacol Res. 2021 Aug 24:105837. doi: 10.1016/j.phrs.2021.105837. Online ahead of print.ABSTRACTGarlic (Allium sativum L.) is one of the oldest plants cultivated for its dietary and medicinal values. This incredible plant is endowed with various pharmacological attributes, such as antimicrobial, antiarthritic, antithrombotic, antitumor, hypoglycemic, and hypolipidemic activities. Among the various beneficial pharmacological effects of garlic, the anticancer activity is presumably the most studied. The consumption of garlic provides strong protection against cancer risk. Taking into account the multi-targeted actions and ...
Source: Cell Research - Category: Cytology Authors: Source Type: research
yk Hayder M. Al-kuraishy Breast cancer persists as a diffuse source of cancer despite persistent detection and treatment. Flavonoids, a type of polyphenol, appear to be a productive option in the treatment of breast cancer, because of their capacity to regulate the tumor related functions of class of compounds. Plant polyphenols are flavonoids that appear to exhibit properties which are beneficial for breast cancer therapy. Numerous epidemiologic studies have been performed on the dynamic effect of plant polyphenols in the prevention of breast cancer. There are also subclasses of flavonoids that have antioxidant and ...
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research
The mesothelioma program at University of Chicago Medicine is recruiting patients for its latest clinical trial involving olaparib, an oral chemotherapy drug targeting cancer-driven genetic mutations. This single-center, phase II clinical trial is open to patients with either pleural mesothelioma or peritoneal mesothelioma. Olaparib, also known by the brand name Lynparza, works by repairing or controlling specific gene mutations. It is known as a protein inhibitor and has been approved by the U.S. Food and Drug Administration for use with breast and ovarian cancers. Mesothelioma, a rare malignancy caused by exposu...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
This study is limited by the small sample size. However, this paper reports on a niche subset of the population and finding larger sample sizes would be difficult to obtain.Wider implications of the findings: This case series illustrates the favourable outcome of pregnancy with IVF after either systemic or local progesterone therapy in early stage endometrial adenocarcinoma or complex hyperplasia. Early involvement of a fertility specialist may prove highly valuable in cases of fertility sparing treatment to increase each patient ’s potential for pregnancy.Trial registration numberNot applicable
Source: Human Reproduction - Category: Reproduction Medicine Source Type: research
This study reveals that the natural compound β-escin has a therapeutic potential because of its ability to prevent OvCa dissemination by targeting both cancer and stromal cells in the OvCa tumor microenvironment.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractPurpose of ReviewYoung women who carry a genetic predisposition to breast cancer need to balance surgical and nonsurgical risk reducing options with childbearing. In this review, we explore how women make decisions without the benefit of official guidelines and in the context of frequently contradictory strategies.Recent FindingsWomen of reproductive age with known BRCA mutations receive incomplete and conflicting advice regarding the urgency and timing of risk reducing mastectomy (RRM). Those who prioritize RRM achieve highly effective prevention and thereby avoid not only a diagnosis of breast cancer but also adj...
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Internal Medicine | Oral Cancer | Ovarian Cancer | Ovaries